Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by LianBio LianBio Announces Voluntarily Delisting from Nasdaq February 28, 2024 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Completion of Strategic Review February 13, 2024 From LianBio Via GlobeNewswire Tickers LIAN LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets December 26, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Departure of Chief Financial Officer December 20, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Departure of Chief Executive Officer December 19, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences December 06, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences December 01, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis October 30, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023 October 25, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Enters into Agreement with Bristol Myers Squibb for Mavacamten in China and Other Asian Markets October 24, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology August 28, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 14, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations August 03, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis July 26, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand July 18, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023 July 17, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations July 12, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore June 26, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis June 08, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China June 06, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio to Participate in Upcoming Investor Conferences June 01, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Reports First Quarter 2023 Financial Results and Provides Corporate Update May 11, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in the Macau Special Administrative Region (SAR) of China May 11, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients April 26, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Promotes Pascal Qian to Chief Commercial Officer April 21, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy April 21, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update March 27, 2023 From LianBio Via GlobeNewswire Tickers LIAN LianBio Announces President and Chief Strategy Officer Departure December 13, 2022 From LianBio Via GlobeNewswire Tickers LIAN LianBio Reports Third Quarter 2022 Financial Results and Provides Corporate Update November 10, 2022 From LianBio Via GlobeNewswire Tickers LIAN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.